Business ❯Pharmaceuticals

Vaccines

Pneumococcal Vaccine mRNA Vaccines IVX-A12 VLP Platform Technology mRNA Technology mRNA technology Respiratory Syncytial Virus

GSK Acquires CureVac's mRNA Vaccines for COVID-19, Flu

The $1.56 billion deal strengthens GSK's vaccine portfolio and provides CureVac with a financial lifeline.

FDA Approves Merck's New Adult Pneumococcal Vaccine Capvaxive

Blackstone Invests $750 Million in Moderna for Flu Vaccine Development

Merck-Moderna Vaccine Reduces Risk of Severe Melanoma Relapse by Half

AstraZeneca to Acquire Icosavax for $1.1 Billion